HUAN Yi
PhD Huan Yi focuses on the development of novel anti-diabetic drugs targeted to SPPARMs, GPR40/119/120/131, FXR, HDAC3 and SGLT2, also takes efforts in the research for diabetes pathogenesis and pharmacological mechanism including glucose/lipid metabolism regulation and pancreatic islet α/β cell functional crosstalk. Recently, has published 8 research papers as the first /corresponding authors, has been authorized 10 patents and participated in the compilation of 3 monographs.
1. Histone deacetylase 3-selective inhibitor RGFP966 ameliorates impaired glucose tolerance through β-cell protection. Toxicology and Applied Pharmacology. 2020, 406:115189.
2. Pose Filter-based Ensemble Learning Enables Discovery of Orally Active, Nonsteroidal Farnesoid X Receptor Agonists. J. Chem. Inf. Model. 2020, 60:1202 - 1214.
3. A novel specific peroxisome proliferator-activated receptor γ (PPARγ) modulator YR4-42 ameliorates hyperglycaemia and dyslipidaemia and hepatic steatosis in diet-induced obese mice. Diabetes Obes Metab. 2019, 21(11):2553-2563.
4. Primary exploration on antidiabetic effect and mechanism of novel GPR40 agonists SZZ15-11. Chin J Clin Pharmocol. 2019, 35(8): 780-784.
5. The dual DPP4 inhibitor and GPR119 agonist HBK001 regulates glycemic control and beta cell function ex and in vivo. Sci Rep. 2017, 7(1): 4351.
6. Design, synthesis and metabolic regulation effect of farnesoid X receptor (FXR) antagonistic benzoxepin-5-ones. Chinese Chemical Letters. 2017, 28: 1519-1522.
7. PPARγ non-agonist ligand: the structure optimization based on PPARγ partial agonist. Acta Pharmaceutica Sinica. 2017, 52 (9): 1424 −1431.
8. Discovery of novel xanthine compounds targeting DPP-IV and GPR119 as anti-diabetic agents. European Journal of Medicinal Chemistry. 2016, 124: 103-116.
